Stockscreener 앱 받기
4.79
4.81%
0.22
시간 외 거래:
4.71
-0.08
-1.67%
전일 마감가:
$4.57
열려 있는:
$4.63
하루 거래량:
3.08M
Relative Volume:
1.43
시가총액:
$461.24M
수익:
-
순이익/손실:
$-81.49M
주가수익비율:
-5.9209
EPS:
-0.809
순현금흐름:
$-73.48M
1주 성능:
+25.72%
1개월 성능:
+43.41%
6개월 성능:
+138.31%
1년 성능:
+15.98%
1일 변동 폭
$4.575
$4.94
1주일 범위
$3.705
$4.94
52주 변동 폭
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
명칭
Rezolute Inc
전화
650-206-4507
주소
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
4.79 | 416.95M | 0 | -81.49M | -73.48M | -0.809 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-25 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2025-12-11 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-12-11 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2025-12-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-11-05 | 개시 | Wedbush | Outperform |
| 2024-08-27 | 개시 | Guggenheim | Buy |
| 2024-07-17 | 개시 | BTIG Research | Buy |
| 2024-06-04 | 개시 | Craig Hallum | Buy |
| 2024-04-09 | 개시 | Maxim Group | Buy |
| 2022-08-02 | 재개 | Canaccord Genuity | Buy |
| 2022-06-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-09-08 | 개시 | ROTH Capital | Buy |
| 2021-05-27 | 개시 | Oppenheimer | Outperform |
| 2021-05-25 | 개시 | H.C. Wainwright | Buy |
모두보기
Rezolute Inc 주식(RZLT)의 최신 뉴스
Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Rezolute (RZLT) and Invivyd (IVVD) - The Globe and Mail
RZLT Maintained by Guggenheim -- Price Target Raised to $11.00 - GuruFocus
Guggenheim raises Rezolute stock price target on trial outlook - Investing.com UK
Guggenheim raises Rezolute stock price target on trial outlook By Investing.com - Investing.com Canada
Exploring 3 High Growth Tech Stocks in US Market - simplywall.st
RZLT stock on the move: What sparks the 38% jump in the past week? - MSN
Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Vericel (VCEL) - The Globe and Mail
Positive Signs As Multiple Insiders Buy Rezolute Stock - Yahoo Finance
RZLT Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Cautious OutlookDiluted EPS Report - newsline.com
Craig-Hallum Keeps Their Hold Rating on Rezolute (RZLT) - The Globe and Mail
REZOLUTE INC (RZLT) Stock Chart - ChartMill
RZLT: Strong interim efficacy in tumor HI and key regulatory milestones expected later this year - TradingView
RZLT: Strong interim efficacy in tumor HI and regulatory clarity for congenital HI expected this year - TradingView
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? - The Globe and Mail
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society - The Manila Times
Rezolute, Inc. Announces Four Presentations at the 2026 Annual Meeting of the Endocrine Society on Ersodetug for Congenital Hyperinsulinism - Quiver Quantitative
Rezolute (RZLT) Receives a Buy from Guggenheim - The Globe and Mail
Phase 3 congenital hyperinsulinism study results to be shared at ENDO 2026 - Stock Titan
RZLT Maintained by Maxim Group -- Price Target Raised to $14.00 - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY) - The Globe and Mail
Rezolute (RZLT) Gains on Upgrade Following Positive Trial Data - GuruFocus
Rezolute upgraded at Citizens after late-stage trial data for lead asset - Seeking Alpha
RZLT Maintained by Wedbush -- Price Target Raised to $6.00 - GuruFocus
RZLT Upgraded by Citizens -- Price Target Announced at $11.00 - GuruFocus
Cantor Fitzgerald reiterates Neutral on Rezolute stock on trial data By Investing.com - Investing.com Australia
A Quick Look at Today's Ratings for Rezolute(RZLT.US), With a Forecast Between $5 to $14 - Moomoo
Rezolute’s stock up on interim Phase III tumour HI data - Yahoo Finance
Cantor Fitzgerald reiterates Neutral on Rezolute stock on trial data - Investing.com
Wedbush Adjusts Price Target on Rezolute to $6 From $5, Maintains Outperform Rating - marketscreener.com
Rezolute Price Target Raised to $6.00/Share From $5.00 by BTIG - Moomoo
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating, Raises Target Price to $14 - Moomoo
Rezolute (RZLT) Shares Rise on Positive Trial Update for Ersodet - GuruFocus
Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study - Benzinga
RZLT Reiterates by HC Wainwright & Co. -- Price Target Maintained at $5.00 - GuruFocus
Rezolute rises after late-stage trial update (RZLT:NASDAQ) - Seeking Alpha
Rezolute Announces Positive Interim Phase 3 upLIFT Results for Ersodetug in Tumor Hyperinsulinism, Six of Eight Responders Achieved IV Glucose Discontinuation 1 - Minichart
Rezolute (RZLT) Shares Phase 3 Study Progress of Ersodetug in Tu - GuruFocus
Rezolute reports interim data from tumor hyperinsulinism trial By Investing.com - Investing.com South Africa
Rezolute Reports Positive Phase 3 Data for Ersodetug - TipRanks
Rezolute reports interim data from tumor hyperinsulinism trial - Investing.com
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism - The Manila Times
Rezolute interim Phase 3 upLIFT data: 6 of 8 meet primary responder criterion; study 50% enrolled - TradingView
Rezolute (NASDAQ: RZLT) reports positive Phase 3 upLIFT tumor HI data - Stock Titan
Rezolute Shares Rise After Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial - marketscreener.com
Rezolute (RZLT) Q1 2026 Earnings: EPS Surpasses Estimates Amid Continued R&D ProgressEstimate Accuracy - The Legal Advocate
RZLT Q1 2026 Earnings: EPS Beat Expectations Despite Negative Stock ReactionEarnings Weakness Phase - newsline.com
Rezolute (RZLT) Edges Higher: Key Levels to Watch After 1.08% GainOutside Reversal - newsline.com
RZLT Q1 2026 Earnings: Narrower Loss Surpasses Expectations as Clinical Pipeline AdvancesEarnings Momentum Score - newsline.com
Rezolute Inc. (RZLT) Slides Amid Sector Pressure: Key Levels to WatchBPI Reversal - newsline.com
RZLT Stock Price, Quote & Chart | REZOLUTE INC (NASDAQ:RZLT) - ChartMill
Opaleye Management Inc. Increases Stake in Rezolute Inc. - GuruFocus
Rezolute Inc (RZLT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rezolute Inc 주식 (RZLT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hogenhuis Wladimir | Director |
Dec 16 '25 |
Buy |
1.69 |
5,650 |
9,548 |
119,675 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Dec 16 '25 |
Buy |
1.70 |
28,000 |
47,600 |
308,352 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.77 |
40,000 |
70,640 |
415,900 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.79 |
5,000 |
8,938 |
7,000 |
| Elam Nevan C | CEO |
Dec 15 '25 |
Buy |
1.59 |
32,000 |
50,880 |
641,119 |
| Karnawat Sunil Ratilal | Chief Commercial Officer |
Dec 15 '25 |
Buy |
1.62 |
12,100 |
19,599 |
71,542 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Jun 25 '25 |
Buy |
4.38 |
2,500 |
10,939 |
15,500 |
| Evans Daron | CFO |
Jun 24 '25 |
Buy |
4.05 |
5,000 |
20,250 |
268,900 |
| Evans Daron | CFO |
Dec 09 '25 |
Buy |
5.04 |
10,549 |
53,167 |
131,900 |
2.60%
0.94%
자본화:
|
볼륨(24시간):